Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted? Feb 27, 2017
Dividend Increases/Decreases for the Week Ending February 24
Let's take a look at companies raising/lowering their dividends this week. Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. Feb 22, 2016
Dividend Increases/Decreases for the Week Ending February 19
Let's take a look at companies raising their dividends this week. Sep 25, 2015
Recent M&A Activity
Let’s take a look at some recent M&A activity across the market. Jul 7, 2015
Teva Pharmaceuticals Committed to Acquiring Mylan
Best Ideas Newsletter portfolio holding Teva Pharmaceuticals is committed to creating a generics industry giant. The deal has great potential, but the companies aren’t seeing eye-to-eye. Apr 9, 2015
Mylan’s Deal for Perrigo Boosts Teva
We continue to like the generics business. Teva Pharma leaps to $65+ per share!!! Mar 20, 2015
Hooray! Biogen’s Breakthrough Alzheimer’s Drug?
Biogen’s potential new drug could help millions of people suffering from Alzheimer’s. Feb 2, 2015
Dividend Increases/Decreases for the Week Ending January 30
Let's take a look at dividend increases/decreases for the week ending January 30. Jan 31, 2014
Dividend Increases/Decreases for the Week Ending January 31
Let's take a look at dividend increases/decreases for the week ending January 31. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
